There are currently 16 vaccine candidates in clinical development, but progress has been constrained by lack of funding and attention.
The regimen was recently recommended by the WHO for treating patients with drug-resistant TB.
The pact will help lower the cost of two shorter treatment regimens for drug-resistant tuberculosis, broadening access.
Despite the milestone, funding remains far short of what's needed, according to a new report.
The shorter 6-month regimen could save enough to supply 400,000 people with almost a year's worth of treatment.
The findings suggest the drug could be part of a shorter and simpler tuberculosis treatment regimen.
A study today in BMC Medicine highlights the toll that the COVID-19 pandemic has taken on the diagnosis of tuberculosis (TB) in high-burden countries, particularly in vulnerable populations.
A clinical trial conducted in seven countries found that two shortened, bedaquiline-containing regimens had superior efficacy in treating rifampicin-resistant tuberculosis (TB) compared with a 9-month injectable-containing regimen, with fewer cases of hearing loss, investigators reported today in The Lancet.
WHO officials say the COVID-19 pandemic's impact on essential TB services has reversed years of progress.
A systematic review and meta-analysis today in Vaccine finds no link between COVID-19 vaccines and infertility in men or women.
Researchers at a Rome hospital analyzed 29 studies from China, Israel, Italy, Russia, Turkey, Canada, and the United States until Jun 8, 2022. Of the studies, 13.8% were deemed of poor quality, 58.6% were of moderate quality, and 27.6% were of good quality.
